Oxford researchers report positive early trial results for COVID-19 vaccine candidate

By Sean Whooley | July 20, 2020

[Photo by Fusion Medical Animation on Unsplash]

Researchers at Oxford University say early-stage results from a Phase I/II clinical trial of a SARS-CoV-2 vaccine candidate display safety and strong immune responses.

Results, published in The Lancet, revealed that the vaccine is safe, causes few side effects and induces strong immune responses in both parts of the immune system in the fight against COVID-19, which is caused by SARS-CoV-2.

Get the full story at our sister site, MassDevice.

Filed Under: clinical trials, Drug Discovery and Development, Infectious Disease
Tagged With: AstraZeneca plc, BioNTech, coronavirus, covid-19, Oxford, Pfizer

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.